Date: 2017-03-14
Type of information: Licensing agreement
Compound:
Company: Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (USA - MA) MaxCyte (USA - MD)
Therapeutic area: Hematologic diseases - Genetic diseases - Rare diseases - Immunological diseases
Type agreement: licensing
Action mechanism:
Disease: CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined immunodeficiency
Details: • On March 14, 2017, Crispr Therapeutics and Casebia Therapeutics, a joint-venture established by Crispr Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, announced they have signed a joint commercial license agreement with MaxCyte. The commercial license builds on an existing research and clinical licensing agreement for select disease areas. Under the terms of the license, Crispr Therapeutics and Casebia will obtain non-exclusive commercial-use rights to MaxCyte’s cell engineering platform to develop CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined immunodeficiency. MaxCyte’s Flow Electroporation™ Technology enables the transfection of a variety of cell types at very high efficiency while maintaining very high viability. CRISPR Therapeutics and Casebia’s lead programs rely on ex vivo gene editing, where the CRISPR components are delivered to hematopoietic stem cells using the MaxCyte technology.
Financial terms: MaxCyte will supply its systems to Crispr Therapeutics and Casebia as part of the license agreement and will receive upfront, milestone, and sales-based payments.
Latest news:
